ATE223416T1 - 5-ht1a und 5-ht1d alpha rezeptorantagonisten - Google Patents

5-ht1a und 5-ht1d alpha rezeptorantagonisten

Info

Publication number: ATE223416T1
Authority: AT; Austria
Prior art keywords: ht1d; ht1a; receptor antagonists; alpha receptor; alpha
Prior art date: 1997-05-29

Application number

AT98304162T

Other languages

English (en)

Inventor

Vincent Patrick Rocco

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-29

Filing date

1998-05-27

Publication date

2002-09-15

1998-05-27 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2002-09-15 Application granted granted Critical

2002-09-15 Publication of ATE223416T1 publication Critical patent/ATE223416T1/de

Links

102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title abstract 2
101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 title abstract 2
102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 title abstract 2
101000822898 Takifugu rubripes 5-hydroxytryptamine receptor 1A-alpha Proteins 0.000 title abstract 2
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
239000005557 antagonist Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Other In-Based Heterocyclic Compounds (AREA)

AT98304162T 1997-05-29 1998-05-27 5-ht1a und 5-ht1d alpha rezeptorantagonisten ATE223416T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US4825697P	1997-05-29	1997-05-29

Publications (1)

Publication Number	Publication Date
ATE223416T1 true ATE223416T1 (de)	2002-09-15

Family

ID=21953552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98304162T ATE223416T1 (de)	1997-05-29	1998-05-27	5-ht1a und 5-ht1d alpha rezeptorantagonisten

Country Status (8)

Country	Link
EP (1)	EP0881224B1 (de)
JP (1)	JP2002500668A (de)
AT (1)	ATE223416T1 (de)
AU (1)	AU7378698A (de)
CA (1)	CA2291674A1 (de)
DE (1)	DE69807578T2 (de)
ES (1)	ES2183289T3 (de)
WO (1)	WO1998053823A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4208457A1 (de) *	2020-09-04	2023-07-12	Gilgamesh Pharmaceuticals, Inc.	Azetidinyl-tryptamine und verfahren zur behandlung psychiatrischer erkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4031224A (en) *	1976-04-29	1977-06-21	American Hoechst Corporation	1,3-Dihydro-heteroarylspiro (isobenzofuran)s
NZ243065A (en) *	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
FR2689509B1 (fr) *	1992-04-01	1994-06-03	Adir	Nouveaux derives spiraniques du 3-amino chromane, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5576321A (en) *	1995-01-17	1996-11-19	Eli Lilly And Company	Compounds having effects on serotonin-related systems

1998
- 1998-05-11 JP JP50070599A patent/JP2002500668A/ja active Pending
- 1998-05-11 WO PCT/US1998/009562 patent/WO1998053823A1/en not_active Ceased
- 1998-05-11 AU AU73786/98A patent/AU7378698A/en not_active Abandoned
- 1998-05-11 CA CA002291674A patent/CA2291674A1/en not_active Abandoned
- 1998-05-27 AT AT98304162T patent/ATE223416T1/de not_active IP Right Cessation
- 1998-05-27 EP EP98304162A patent/EP0881224B1/de not_active Expired - Lifetime
- 1998-05-27 ES ES98304162T patent/ES2183289T3/es not_active Expired - Lifetime
- 1998-05-27 DE DE69807578T patent/DE69807578T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2002500668A (ja)	2002-01-08
DE69807578D1 (de)	2002-10-10
AU7378698A (en)	1998-12-30
CA2291674A1 (en)	1998-12-03
WO1998053823A1 (en)	1998-12-03
EP0881224B1 (de)	2002-09-04
ES2183289T3 (es)	2003-03-16
EP0881224A1 (de)	1998-12-02
DE69807578T2 (de)	2003-05-22

Legal Events

Date	Code	Title	Description
2003-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69636801D1 (de)	2007-02-08	Dioxinoderivate und ihre Verwendung als Dopamine Agonisten
ES2179881T3 (es)	2003-02-01	Antagonistas de endotelina.
DE69333062D1 (de)	2003-07-31	4-mercaptoacetylamino-[2]benzazepinon(3)- derivate, und verwendung als enkephalinase-inhibitoren
MA24564A1 (fr)	1998-12-31	Derives substitues en c-4 ''de 9-desoxo-9a-aza-9a-homoerythromycine a
FI964815L (fi)	1996-12-02	Piperatsiinijohdoksia 5-HT1A antagonisteina
DE50000102D1 (de)	2002-03-14	Pyrogen hergestelltes Aluminiumoxid
ES2138247T3 (es)	2000-01-01	Composicion y uso.
ES2159749T3 (es)	2001-10-16	Derivados de bencilamino-2-metil-propanamidas 2-(4-sustituidas).
DE69610316D1 (de)	2000-10-19	Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste
ID23053A (id)	2000-01-20	Karboksamida yang digunakan sebagai agonis 5-ht <if>
DE69600020D1 (de)	1997-06-26	Wasserfreie kosmetische Zusammensetzungen, welche TiO2 Nanopigmente und verformbare hohle Mikrokugeln enthalten
ATE259825T1 (de)	2004-03-15	Hemihydrat von 16.alpha.-bromoepiandrosterone
DE69719083D1 (de)	2003-03-20	Neuartige orale Zubereitungen von Calcitonin
DE69839767D1 (de)	2008-09-04	Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
NO20010654L (no)	2001-02-07	Ny anvendelse av taxoidderivater
NO985970D0 (no)	1998-12-18	Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
DE69007695D1 (de)	1994-05-05	Fucosidase-Inhibitoren.
DE69807578D1 (de)	2002-10-10	5-ht1a und 5-ht1d alpha rezeptorantagonisten
DE60024108D1 (de)	2005-12-22	Leukotrien rezeptor
BR9708595A (pt)	1999-08-03	Utilização de derivados de 2,5- di-hidroxibenzenossulfonicos
NO20001937D0 (no)	2000-04-13	2-substituerte 1,2-benzisotiazol-derivater og deres anvendelse som serotonin-antagonister (5-HT1A, 5-HT1B og 5-HT1D)
ATE256101T1 (de)	2003-12-15	Gelbe polymorphe form von 5-amino-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypro yl)-isophthalamid
DE69024524D1 (de)	1996-02-15	Substituierte Tetrahydroindanderivate und ihre Verwendung als Zwischenprodukte
DE69831427D1 (de)	2005-10-06	Benzo(c)quinolizinderivative und deren verwendung als 5 alpha-reduktase-hemmer
DK0573562T3 (da)	1996-05-13	Dihydroquinolin NMDA-antagonister